Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) 56.1% HIGHER; announced finalization of the protocol for the Company's Phase II trial of ANA598 in combination with pegylated interferon-alpha and ribavirin in hepatitis C patients. Allowance of the protocol has been received from the US FDA, and patient dosing is expected to commence within the next several weeks. Also reported a Q2 loss of $0.21, 7 cents better than the analyst estimate of ($0.28). The stock was also upgraded to Accumulate at ThinkEquity.
Integra Bank Corporation (Nasdaq: IBNK) 43.1% HIGHER; reports Q2 loss of $2.12, cents better than the analyst estimate of ($1.08). Revenue for the quarter was $16.8 million, versus the consensus of $27.10 million.
Inovio Biomedical (AMEX: INO) 40% HIGHER; trading in INO has ...
Unusual 11 Mid-Day Movers 7/31: ANDS, IBNK, INO, DSCM Higher; SYNA, ARIA, SFI, PIR Lower
